论文部分内容阅读
目的 探讨上皮钙粘素 (E Cad)在非小细胞肺癌 (NSCLC)组织及淋巴结转移灶中的表达及其临床意义。方法 应用免疫组织化学S P法检测 3 0例正常肺组织、61例NSCLC患者原发灶及其中 41例淋巴结转移灶中E Cad的表达。结果 正常肺组织均显示清楚的细胞膜染色 ,NSCLC原发灶及淋巴结转移灶中E Cad异常表达率分别为 5 2 .46% ( 3 2 /61)和 63 .41% ( 2 6/41) ,二者比较差异无显著性 (P >0 .0 5 )。E Cad异常表达率与P TNM分期、病理分级及淋巴结转移有密切关系 (P <0 .0 0 1～ 0 .0 5 ) ,但与肺癌组织学类型无明显关系 (P >0 .0 5 )。结论 E Cad基因作为肿瘤抑制基因 ,其异常表达可能是反映NSCLC生物学行为、预测其转移潜能的很有价值的指标。
Objective To investigate the expression and clinical significance of E Cad in non-small cell lung cancer (NSCLC) tissues and lymph node metastases. Methods Immunohistochemistry SP method was used to detect the expression of E Cad in primary lung tissue and 41 cases of metastatic lymph nodes in 30 cases of normal lung tissues and 61 cases of NSCLC. Results The normal lung tissues showed clear cell membrane staining. The abnormal expression rate of E Cad in NSCLC primary tumors and lymph node metastases were 52.46% (32/61) and 63.41% (26/41), respectively. There was no significant difference between the two (P > 0.05). The abnormal expression rate of E Cad was closely related to P TNM stage, pathological grade, and lymph node metastasis (P 0.01-0.05), but it was not significantly related to the histological type of lung cancer (P > 0.05). . Conclusion As a tumor suppressor gene, E Cad gene may be a valuable indicator reflecting the biological behavior of NSCLC and predicting its metastatic potential.